Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124)

Fj, Meyers; D, Lew; Pn, Lara; Williamson, S.; Marshall, Ernest; Sp, Balcerzak; Se, Rivkin; Samlowski, Wolfram E.; Crawford, E. David

doi:10.1023/a:1006128024879

Cited by 6 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a phase I trial of 46 patients receiving edatrexate plus carboplatin in advanced solid tumors, only 15% had Grade 3/4 OM with the use of cryotherapy, 22 less OM than was seen in trials not using cryotherapy. 23, 24 Two other trials found mixed results with cryotherapy in patients receiving edatrexate. 25, 26 …”

Section: Oral Mucositismentioning

confidence: 99%

Supportive Cryotherapy: A Review From Head to Toe

Kadakia

Rozell

Butala

et al. 2014

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

Context Conventional chemotherapy leads to multiple adverse mucocutaneous complications including oral mucositis, alopecia, ocular toxicity, and onycholysis. Limited pharmacologic interventions are available for preventing these clinical problems. Objectives This study aimed to critically review the role of cryotherapy (regional hypothermia) for alleviating these adverse symptoms. Methods A narrative review was performed, with an emphasis on randomized controlled trials. A comprehensive search using PubMed, Ovid, Embase, and MEDLINE® was completed. References of all cited articles also were reviewed. Data from the review were comprised of articles published between 1970 to May 2013. Results Available evidence suggests that regional hypothermia decreases the burden of chemotherapy-related oral mucositis, alopecia, ocular toxicity, and onycholysis. The major limitations of studies include the absence of blinded control groups and variable clinical endpoints. Conclusion Regional hypothermia decreases the burden of these four chemotherapy-induced complications and is well tolerated. More research is needed to determine what subgroups of cancer patients are most likely to respond to different types of regional hypothermia, the ideal duration of cooling needed, and to further improve the ease of use of the cooling devices.

show abstract

Section: Oral Mucositismentioning

confidence: 99%

Supportive Cryotherapy: A Review From Head to Toe

Kadakia

Rozell

Butala

et al. 2014

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

show abstract

“…The main compounds are 10-ethyl-10-deazaaminopterin (edatrexate) and 10-propargyl-10-deazaaminopterin (pralatrexate, PDX), which have undergone several clinical investigations. 65,66 The latter compound, under the trade name Folotyn ® , was the first drug approved for the treatment of relapsed or refractory peripheral T-cell lymphoma, or peripheral T-cell lymphoma.…”

Section: Classical Dhfr Inhibitorsmentioning

confidence: 99%

Antimetabolites That Interfere with Nucleic Acid Biosynthesis

Avendaño

Menéndez

2015

Medicinal Chemistry of Anticancer Drugs

View full text Add to dashboard Cite

Germ cell tumor clinical trials in North America

Bosl¹

1999

Sem. Surg. Onc.

View full text Add to dashboard Cite

The management of germ cell tumors (GCT) in men has been the focus of intense clinical investigation over the past 25 years. Following clinical trials which demonstrated that GCTs are curable, considerable effort has been directed at refinement of the multidisciplinary treatment plan. During the past decade, there has been a major emphasis on identifying those clinical prognostic features most closely associated with a high likelihood of a complete response (good risk) and a low likelihood of complete response (poor risk). Randomized good‐ and poor‐risk clinical trials have been conducted which clarify the role of bleomycin and the number of cycles of therapy in good‐risk patients and the role of high‐dose cisplatin (200 mg/m2/cycle) and ifosfamide in poor‐risk patients. The efficacy of high‐dose chemotherapy with stem cell rescue has led to a randomized trial of its use following standard induction therapy as compared to standard induction therapy in previously untreated poor‐risk patients. Salvage chemotherapy for patients in first or second relapse, or those who have not achieved an initial complete response, initially tested the role of ifosfamide; efforts are now focused on the role of paclitaxel and high‐dose therapy in specific patient subgroups. High‐dose chemotherapy with stem cell rescue is the treatment of choice for patients in second relapse with gonadal primary tumors who have responsive disease and factors which predict a reasonable likelihood of achieving a disease‐free status. A general understanding of tumor biology and specific knowledge regarding GCTs will be very important in the next decade of discovery as the pathways of malignant transformation, progression, and drug resistance become better known and serve as targets for new therapy. Semin. Surg. Oncol. 17:257–262, 1999. © 1999 Wiley‐Liss, Inc.

show abstract

Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124)

Cited by 6 publications

References 15 publications

Supportive Cryotherapy: A Review From Head to Toe

Supportive Cryotherapy: A Review From Head to Toe

Antimetabolites That Interfere with Nucleic Acid Biosynthesis

Germ cell tumor clinical trials in North America

Contact Info

Product

Resources

About